Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.

 

3. Bard shares gain on nearly 50% earnings rise

C.R. Bard shares are up more than 3% this morning on Wall Street after the medical device company reported that its 3rd-quarter earnings rose 47.0% compared with the same period last year.

Bard reported profits of $131.3 million, or $1.69 per share, on sales of $830.0 million for the 3 months ended Sept. 30, representing sales growth of 9.5% compared with Q3 2013. Adjusted to exclude 1-time items, earnings per share were $2.15, a nickel ahead of The Street. Read more

2. Sorin drops $20m on stake in Respicardia

Sorin Group said it invested $20 million in a minority stake and controlling option in Minnetonka, Minn.-based Respicardia, which is developing implantable devices to treat central sleep apnea.

Milan, Italy-based Sorin also said it won CE Mark approval for its new Memo 3D ReChord mitral valve annuloplasty device. Read more

1. U.S. Patent Office denies Medtronic request in Endotach stent case

The U.S. Patent & Trademark Office denied Medtronic’s request for inter partes review of a disputed stent patent in its ongoing case against Endotach.

Medtronic filed a 2nd petition for a review of patent ‘417 in April. The 2nd petition included 3 new grounds supporting its case against Endotach. Read more